Welcome to our dedicated page for Corvus Pharmaceu SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) SEC filings page on Stock Titan provides access to the company’s public reports as filed with the U.S. Securities and Exchange Commission. Corvus is a Delaware-incorporated, clinical-stage biopharmaceutical company whose common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Global Market. Its filings give structured detail on operations, risk factors, capital structure and governance as it advances immunotherapy programs for cancer and immune diseases.
Through this page, you can review current and periodic reports such as Forms 8-K, which Corvus uses to announce material events including financial results, business updates and board of director changes. For example, recent 8-K filings have furnished press releases on quarterly financial results and described the appointment of a new director to the Board and its committees.
Investors researching CRVS can also use this section to locate annual reports (Form 10-K) and quarterly reports (Form 10-Q), where available, which typically discuss the company’s clinical-stage pipeline, including the ITK inhibitor soquelitinib, the adenosine A2a receptor inhibitor ciforadenant and the anti-CD73 antibody mupadolimab. These filings often outline key clinical programs such as the registration Phase 3 trial in relapsed/refractory peripheral T cell lymphoma and trials in atopic dermatitis and Autoimmune Lymphoproliferative Syndrome.
Stock Titan enhances these documents with AI-powered summaries that highlight important sections, helping readers quickly identify information on clinical development, collaborations, equity structure and risk disclosures without reading every page. Real-time updates from EDGAR mean new CRVS filings, including any future Forms 4 related to insider transactions or proxy statements on executive and director compensation, can be reviewed promptly from a single, organized interface.
Corvus Pharmaceuticals, Inc. reported an insider equity award to its President, CEO and Director, Richard A. Miller. On 12/04/2025 he was granted a stock option to purchase 1,000,000 shares of Corvus common stock at an exercise price of $8.81 per share.
The option expires on 12/04/2035 and the underlying shares vest in equal monthly installments. Specifically, 1/36th of the shares vest each month starting on December 4, 2025, as long as he continues his service relationship with the company. Following this grant, he directly holds 1,000,000 derivative securities in the form of stock options.
Corvus Pharmaceuticals reported that its Chief Business Officer, Jeffrey Arcara, acquired a stock option covering 100,000 shares of common stock on December 4, 2025. The option has an exercise price of $8.81 per share and is held directly.
The underlying shares vest in equal monthly installments, with 1/36 of the shares vesting each month starting from December 4, 2025, as long as Arcara continues his service with the company. The option expires on December 4, 2035, and following this transaction he beneficially owned 100,000 stock options.
Corvus Pharmaceuticals (CRVS) filed its Q3 2025 10‑Q, highlighting a clinical‑stage pipeline and continued operating losses. Cash, cash equivalents and marketable securities were $65.7 million as of September 30, 2025. Q3 operating expenses were $10.6 million, driven by R&D $8.5 million and G&A $2.1 million.
The company reported a Q3 net loss of $10.2 million. For the nine months, net loss was $3.0 million, reflecting a $27.1 million non‑cash gain from the change in fair value of its warrant liability. All common warrants from the May 2024 financing were exercised, delivering $54.3 million in proceeds and reducing the warrant liability to zero from $28.9 million at year‑end 2024; current liabilities fell to $8.1 million from $35.4 million.
Operating cash outflow was $23.6 million for the nine months, while financing inflows were $36.4 million. The company disclosed substantial doubt about its ability to continue as a going concern and noted it may seek additional funding, including under its $100 million at‑the‑market program with no sales to date. Shares outstanding were 74,681,872 as of November 4, 2025.
Corvus Pharmaceuticals (CRVS) filed an 8-K to furnish a press release covering its financial results for the three and nine months ended September 30, 2025, along with a business update. The press release is provided as Exhibit 99.1.
The company states the information under Item 2.02 and Exhibit 99.1 is furnished and not filed under the Exchange Act. Corvus’s common stock trades on the Nasdaq Global Market under the symbol CRVS.
Corvus Pharmaceuticals, Inc. (CRVS) reported an insider equity transaction by Director David Scott Moore on 10/02/2025. The filing discloses an award of 30,000 stock options with an exercise price of
Corvus Pharmaceuticals, Inc. (CRVS) filed an Initial Statement of Beneficial Ownership (Form 3) reporting that David Scott Moore is a director and that, as of the
Corvus Pharmaceuticals, Inc. appointed David Moore to its Board of Directors effective October 2, 2025. He will serve as a Class III director with a term extending to the 2028 annual meeting of stockholders and will also join the Compensation Committee and the Nominating and Corporate Governance Committee.
Under the company’s non-employee director compensation program, Mr. Moore will receive a $35,000 annual cash retainer for Board service, plus $6,000 annually for serving on the Compensation Committee and $4,000 annually for serving on the Nominating Committee, each earned quarterly and prorated for the current quarter. He will also receive an initial stock option to purchase 30,000 shares of common stock under the 2016 Equity Incentive Award Plan and will be eligible for future equity awards according to the same program. Mr. Moore will enter into the company’s standard indemnification agreement for directors and executive officers.
Corvus Pharmaceuticals, Inc. Schedule 13G/A (Amendment No. 5) was filed by Samlyn Capital, LLC, Samlyn, LP and Robert Pohly reporting zero beneficial ownership of Corvus common stock (CUSIP 221015100) as of the event date 06/30/2025. The filing identifies the reporting persons, their Delaware or U.S. organization, principal office addresses, and confirms 0 shares, 0% ownership with no sole or shared voting or dispositive power. The filing includes Exhibit A (Joint Filing Agreement) and Exhibit B (Control Person Identification) and is signed by Robert Pohly on 08/14/2025.
FAQ
What is the current stock price of Corvus Pharmaceu (CRVS)?
What is the market cap of Corvus Pharmaceu (CRVS)?
